Overview

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.
Phase:
Phase 3
Details
Lead Sponsor:
LG Life Sciences
Treatments:
Rosuvastatin Calcium
Valsartan